Company Overview and News
PERTH, WESTERN AUSTRALIA--(Marketwired - April 19, 2017) - Paladin Energy Ltd ("Paladin" or "the Company") (TSX VENTURE: PDN) (ASX: PDN) announces the release of its Quarterly Activities Report for the period ended 31 March 2017.
PERTH, WESTERN AUSTRALIA--(Marketwired - April 02, 2017) - Paladin Energy Ltd (Paladin or the Company) (ASX: PDN) (TSX: PDN) wishes to advise that the minority sale of 30% in Manyingee Project has not completed prior to the mutually agreed drop dead date of 31 March 2017 to satisfy all the conditions to closing.
PERTH, WESTERN AUSTRALIA--(Marketwired - January 19, 2017) - Paladin Energy Ltd (Paladin or the Company) (ASX: PDN) (TSX: PDN) is pleased to advise MGT Resources Limited (MGT) has received shareholder approval to acquire 30% of the Manyingee Uranium Project (Manyingee) for US$10 million cash. The approval represents another positive milestone towards closing the transaction.
PERTH, WESTERN AUSTRALIA--(Marketwired - January 18, 2017) - Paladin Energy Ltd ("Paladin" or "the Company") (TSX: PDN)(ASX: PDN) announces the release of its Quarterly Activities Report for the period ended 31 December 2016.
Ladies and gentlemen thank you for standing by and welcome to the September Quarter Conference Call and Investor Update. At this time all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions]. I must advice that this conference is being recorded today, Wednesday, 16 November, 2016. I would now like to hand the conference over to your first speaker today CEO of Paladin Energy, Mr.
PERTH, WESTERN AUSTRALIA--(Marketwired - November 14, 2016) - Paladin Energy Ltd (Paladin or the Company) (ASX: PDN) (TSX: PDN) is pleased to advise that MGT Resources group of companies have signed a sale of tenement agreement with Paladin group of companies in relation to a joint venture over the Manyingee Mining Leases (M08/86, M08/87 M08/88) (Manyingee Uranium Project) in North Western Australia.
PERTH, WESTERN AUSTRALIA--(Marketwired - November 10, 2016) - Paladin Energy Ltd (Paladin or the Company) (ASX: PDN) (TSX: PDN) wishes to provide an update regarding the previously announced strategic initiatives including: the potential sale of a 24% interest in the Langer Heinrich Mine (LHM) for US$175M to CNNC Overseas Uranium Holdings Ltd (COUH); and the sale of a 75% interest in the Manyingee project to MGT Resources Ltd (MGT).
Cauldron Energy Ltd (ASX:CXU) has executed a A$2.5 million placement agreement with a new Chinese sophisticated investor. Under the agreement, Cauldron will issue 31.25 million shares priced at $0.08, which represents a 29% premium to the company’s last closing price. The agreement is conditional to the investor approving the company’s financial budget for the period to 31 December 2017. Funds raised will primarily be used at the Bennet Well uranium deposit within the Yanrey Project in Western Australia to complete its passive seismic survey work, commence field leach trials and for working capital.
Hi, good morning everybody and welcome to the Paladin annual results conference call for FY2016. It’s Alex Molyneux here and joined with me Craig Barnes, our Chief Financial Officer; both nearly close Darryl Butcher, would join us on this call but he is on site at the moment at Langer Heinrich. We’ve got our presentations available on our ASX news releases. I believe it’s also available via the link on our announcement and on our website.
PERTH, AUSTRALIA--(Marketwired - July 20, 2016) - Paladin Energy Ltd (Paladin or the Company) (ASX: PDN) (TSX: PDN) announces the outcome of its strategic initiatives process with respect to partnerships, strategic investment, funding and corporate transactions, with the result being two planned transactions to raise in excess of US$200 million. One pertains to a proposed sale of 24% of Langer Heinrich Mine (LHM) and one pertains to a potential sale of up to 75% of Manyingee as set out below.
23h - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...